Available online 30 September 2023, 104772

Author links open overlay panel, , Section snippetsTo the Editor2

We read with great interest the recent article titled “SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses” by Burton et al [1], in which the authors investigated and compared the effects of three second mitochondria-derived activator of caspases (SMAC) mimetics (birinapant, BV6, and LCL161) on different measures of CD4 and CD8 T-cell function. Endogenous SMAC promotes apoptotic signaling through inhibition of inhibitors of apoptosis proteins (IAPs),

CRediT authorship contribution statement

Jean Bourhis: Writing – original draft, Writing – review & editing. Xu-Shan Sun: Writing – original draft, Writing – review & editing. Yungan Tao: Writing – original draft, Writing – review & editing.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J. Bourhis has an advisory/consultancy role with Bristol Myers Squibb, MSD, Merck, AstraZeneca, Debiopharm, Roche, and Nanobiotix. X.-S. Sun has declared no conflicts of interest. Y. Tao has an advisory/consultancy role with and has received honoraria from MSD, Merck, and Ipsen.

Acknowledgements

Medical writing support was provided by Eric Deutsch, PhD, CMPP, of Clinical Thinking and was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

In March 2021, Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) gained exclusive rights to develop and commercialize xevinapant worldwide, including in the U.S. (https://www.merckgroup.com/en/news/xevinapant-01-03-2021.html).

References (22)R.K. Amaravadi et al.A phase I study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma

Mol. Cancer Ther.

(2015)

View full text

© 2023 Published by Elsevier Inc.